• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Future medicinal chemistry >Drugs for neglected diseases: part II.
【24h】

Drugs for neglected diseases: part II.

机译：被忽视疾病的药物：第二部分。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

As mentioned in the foreword to the first issue in this two-part special focus, it is a challenge to obtain an overview of the field of neglected diseases from the perspective of medicinal chemistry [1]. Yet, however challenging the situation is, the R&D landscape for neglected diseases has been improving in recent years. According to the Global Funding of Innovation for Neglected Diseases database, total worldwide funding in 2009 for all neglected diseases (including HIV/AIDS) stood at USdollar3.2 billion, representing an increase of 8.2% compared with 2008, in spite of the economic downturn in that period [101]. The total amount appears substantial, but is quite meager when actually spread over 31 neglected diseases. Furthermore, 72% of those funds are taken up by the three largest diseases: HIV/AIDS, malaria and TB. The remaining funds are then spread over the other neglected diseases and include fields such as vaccines, diagnostics and platform technologies. Besides funding, the increased research effort is also reflected in the number of publications that cover a greater range of diseases, compared with 5 years ago (e.g., [102]).
机译：正如在这个由两部分组成的特别关注的第一期的序言中所提到的那样，从药物化学的角度来了解被忽视疾病领域是一个挑战[1]。但是，无论形势如何具有挑战性，近年来，被忽视疾病的研发环境一直在改善。根据全球被忽视疾病创新资金数据库，尽管经济不景气，2009年全球所有被忽视疾病（包括艾滋病毒/艾滋病）的资金总额为32亿美元，比2008年增长8.2％。在那个时期[101]。总数看来是可观的，但是当实际上分布在31种被忽视的疾病上时，其数量却很少。此外，这些资金中的72％被三种最大的疾病占用：艾滋病毒/艾滋病，疟疾和结核病。剩余的资金然后分配给其他被忽视的疾病，包括疫苗，诊断和平台技术等领域。除资金外，与5年前相比，更多的研究工作还反映在涵盖更大范围疾病的出版物数量上（例如[102]）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号